Loss of heterozygosity of selected tumor suppressor genes in parathyroid carcinoma

Surgery

Volumn 144, Issue 6, 2008, Pages 949-955

  Yip, Linwah ^a   Seethala, Raja R ^a   Nikiforova, Marina N ^a   Nikiforov, Yuri E ^a   Ogilvie, Jennifer B ^a   Carty, Sally E ^a   Yim, John H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INVASION; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID CARCINOMA; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

GENES, TUMOR SUPPRESSOR; HUMANS; HYPERPARATHYROIDISM, PRIMARY; LOSS OF HETEROZYGOSITY; MIDDLE AGED; PARATHYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 56449083711     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.08.030     Document Type: Article

References (16)

1. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86 (2001) 485-493
2. Lee P.K., Jarosek S.L., Virnig B.A., Evasovich M., and Tuttle T.M. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109 (2007) 1736-1741
3. Hundahl S.A., Fleming I.D., Fremgen A.M., and Menck H.R. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer 86 (1999) 538-544
4. Dionisi S., Minisola S., Pepe J., De Geronimo S., Paglia F., Memeo L., et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 77 (2002) 866-869
5. Chen J.D., Morrison C., Zhang C., Kahnoski K., Carpten J.D., and Teh B.T. Hyperparathyroidism-jaw tumour syndrome. J Intern Med 253 (2003) 634-642
6. Carpten J.D., Robbins C.M., Villablanca A., Forsberg L., Presciuttini S., Bailey-Wilson J., et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32 (2002) 676-680
7. DeLellis R.A. Parathyroid carcinoma: an overview. Adv Anat Pathol 12 (2005) 53-61
8. Ippolito G., Palazzo F.F., Sebag F., DeMicco C., and Henry J.F. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 94 (2007) 566-570
9. Hunt J.L., Carty S.E., Yim J.H., Murphy J., and Barnes L. Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol 29 (2005) 1049-1055
10. Cetani F., Pardi E., Viacava P., Di Pollina G., Fanelli G., Picone A., et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol 60 (2004) 99-106
11. Haven C.J., van PuijenBroek M., Tan M.H., Teh B.T., Fleuren G.J., van Wezel T., et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol 67 (2007) 370-376
12. Yang Y., and Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 265 (2007) 34-41
13. Gill A.J., Clarkson A., Gimm O., Keil J., Dralle H., Howell V.M., et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30 (2006) 1140-1149
14. Shattuck T.M., Valimaki S., Obara T., Gaz R.D., Clark O.H., Shoback D., et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349 (2004) 1722-1729
15. Cetani F., Ambrogini E., Viacava P., Parki E., Fanelli G., Naccarato A.G., et al. Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?. Eur J Endocrinol 156 (2007) 547-554
16. Hewitt K.M., Sharma P.K., Samovitz W., and Hobbs M. Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 116 (2007) 928-933